Member Info for RayPointer

He could be our new chairman

And let's hope that this is the first of many patients to benefit from Lindy's brilliant Moditope science.

From memory I think Scancell said we would get an update on the Modi1 trial before year end.
It might be quite exciting, but I give no SP prediction. Goodness knows how many golden crosses will be involved :-)

£80, £8, 24p, 14p, 6p, 5p; we are never short of SP predictions.
Wannabe Zak Mirs abound :-)
Soon we will have enough data to publish results. I would imagine Lindy is very excited about this.

Ivy
Maybe you get mistaken for Inan :-)

CEPI? (Scancell already mentioned in a CEPI blog)
Roche/Genetech? (the Ira Mellman connection via the Grand Challenge)

What if Lindy's mother had complained about a headache on that momentous night sixty odd years ago?

I would guess there is a long list of companies interested in Scancell's products and especially Moditope.
At the previous AGM, Lindy joked that Biontech would not be able to afford Modi1.
Biontech are obviously doing something about that by increasing their cash pile :-)

Yes, thanks Botski

Interesting that MD made a comment at the AGM. For memory, I don't think that has happened before. No doubt there will be a doomie slant on this.

Methinks the increase in trials sites is a good indication of how the SCIB1 and Modi1 trials are progressing.
Hopefully we will hear more about this before too long.

Everybody ready for a mega RNS on Tuesday morning? :-)

debs, please delay your growing up as long as possible :-)
ATB

Predictive text strikes again :-)

"Many thanks how can I identify you? X"
Team ramp will be smiling and team soon will be scowling

Interesting but no mention of high avidity!

Hi Konar
I think you will find that the human responses will be from in vitro blood from healthy individuals.

Morning bobbust
Not an antibody but another promising Moditope target.

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/bip-sitc-2022-poster.pdf

The recent RNS on Modi1 that stated a patient in Cohort had an immune response reminded me of this RNS on the original SCIB1 trial.

https://www.lse.co.uk/rns/SCLP/update-on-scib1-phase-12-clinical-trial-fbs37wrpg5wqvxt.html

"Although the study was not designed primarily to measure tumour response, one patient in the 4mg dose cohort with multiple tumour lesions at study entry had a differential response to treatment including partial or complete regression of all lung metastases. A further two patients who had all their tumours surgically removed prior to SCIB1 treatment have remained disease-free more than a year after first dosing. The vaccine produced very few side effects, none of which were serious."

The SCIB1 trial ended up with that wonderful swim chart. But no deal despite having a super salesman in RG :-)
But this was at a time when cancer vaccines just weren't sexy enough.
What are the chances that it will be different this time around? Pretty good, I would say.

I wouldn't worry.
There is increasing evidence that Lindy is a very special scientist.
Not long to wait for confirmation of that :-)

https://bettersoundproofing.com/is-cardboard-good-for-soundproofing/

:-)